Effects of cyclophosphamide administration on ovarian dysfunction in pediatric patients with connective tissue...

Area of Science:

• Pediatric Rheumatology
• Reproductive Endocrinology
• Pharmacology

Background:

• Juvenile-onset connective tissue diseases (JCTD) often require immunosuppressive therapy.
• Cyclophosphamide (CY) is a commonly used alkylating agent in treating JCTD.
• Potential long-term effects of childhood CY exposure on reproductive health are a significant concern.

Purpose of the Study:

• To systematically review the existing literature on the effects of childhood cyclophosphamide administration on ovarian function in patients with JCTD.
• To identify and synthesize findings regarding clinical ovarian dysfunction, hormonal profiles, and ovarian reserve.

Main Methods:

• A comprehensive systematic scoping review of the MEDLINE database was performed.
• Search terms included cyclophosphamide, juvenile-onset connective tissue diseases, and ovarian function.
• Six observational studies focusing on systemic lupus erythematosus patients were included after a two-stage screening process.

Main Results:

• Included studies exhibited a high risk of confounding bias due to a lack of adjustment for confounding variables.
• No clear differences in clinical ovarian dysfunction were observed between CY-exposed and non-CY groups.
• Statistical differences indicated decreased ovarian reserve and elevated follicle-stimulating hormone (FSH) levels in CY-exposed patients.

Conclusions:

• Current evidence suggests cyclophosphamide use in childhood may not have conclusively significant clinical effects on ovarian function.
• Further investigation is required to understand CY's impact on hormonal levels, fertility, and pregnancy outcomes.
• The review highlights the need for careful monitoring of reproductive health in JCTD patients treated with CY during childhood.